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Abstract
Introduction:  The  adherence  to  medical  treatment  in  allergic  rhinitis  (AR)  is  poorly  evaluated
in clinical  practice.
Objectives:  To  evaluate  adherence  to  intranasal  corticosteroids  (ICS)  in  the  treatment  of  aller-
gic rhinitis  AR  patients.
Methods:  This  prospective  study  was  conducted  on  adult  patients  who  were  admitted  to  the
outpatient clinic  of  the  otolaryngology  department  tertiary  hospital.  Patients  diagnosed  with
moderate  to  severe  persistent  AR  and  who  had  not  used  any  nasal  sprays  were  enrolled  in  the
study. The  patients  were  provided  with  mometasone  furoate  nasal  sprays.  On  the  30th  day,
all participants  ﬁlled  out  a  questionnaire  regarding  the  factors  that  may  have  inﬂuenced  their
adherence  to  the  treatment.  Afterwards,  each  patient  ﬁlled  out  the  Turkish-language-validated
Morisky  Medical  Adherence  Scale  (MMAS-8)  form.  Each  factor  that  may  have  affected  adherence
to the  prescribed  medication  was  evaluated  according  to  the  MMAS-8  score  and  all  variables
were analyzed  statistically.
Results:  Fifty-nine  adult  patients  with  a  mean  age  of  32.5  years  (range  21--52  years)  were
included in  the  study.  The  mean  overall  MMAS-8  score  was  3.64.  Two  factors  were  signiﬁcan-
tly related  to  low  adherence:  number  of  dependent  children  (p  =  0.001)  and  beneﬁt  from  the
medication  (p  =  0.001).  In  addition,  patients  with  higher  education  levels  seemed  to  be  more
adherent than  the  rest  of  the  group.
Conclusion:  Clinicians  must  keep  in  mind  the  factors  related  to  non-adherence  in  order  to
achieve better  treatment  outcomes.  Therefore,  based  on  our  results,  patients  must  be  informed
that medications  should  be  taken  properly  regardless  of  the  beneﬁt,  and  the  treatment  should
be scheduled  with  respect  to  daily  activities,  particularly  for  patients  caring  for  more  than  two
children.
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Adesão  clínica  a  corticosteroides  intranasais  em  pacientes  adultos
Resumo
Introduc¸ão:  A  adesão  ao  tratamento  clínico  de  Rinite  Alérgica  (RA)  é  mal  avaliada  na  prática
clínica.
Objetivos:  Avaliar  a  adesão  aos  corticosteroides  intranasais  (CEI)  no  tratamento  de  pacientes
com rinite  alérgica  (RA).
Método:  Este  estudo  prospectivo  foi  realizado  em  pacientes  adultos  admitidos  no  ambulatório
do setor  de  otorrinolaringologia  de  um  hospital  terciário.  Os  pacientes  diagnosticados  com  RA
moderada a  persistente  grave  e  que  não  tinham  usado  nenhum  spray  nasal  foram  incluídos  no
estudo. Os  pacientes  receberam  sprays  nasais  de  furoato  de  mometasona.  No  30◦ dia,  todos  os
participantes  preencheram  um  questionário  sobre  os  fatores  que  podem  ter  inﬂuenciado  a  sua
adesão ao  tratamento.  Depois  disso,  cada  paciente  preencheu  o  formulário  da  Escala  de  Adesão
Clínica Morisky  validado  para  a  língua  turca  (MMAS-8).  Cada  fator  que  pode  ter  afetado  a  adesão
à medicac¸ão  prescrita  foi  avaliado  de  acordo  com  o  escore  de  MMAS-8  e  todas  as  variáveis  foram
analisadas  estatisticamente.
Resultados:  Cinquenta  e  nove  pacientes  adultos  com  idade  média  de  32,5  anos  (variac¸ão  de  21-
52 anos)  foram  incluídos  no  estudo.  O  escore  total  médio  de  MMAS-8  foi  de  3,64.  Dois  fatores
foram signiﬁcativamente  relacionados  com  a  baixa  adesão:  número  de  crianc¸as  dependentes
(p =  0,001)  e  benefício  da  medicac¸ão  (p  =  0,001).  Além  disso,  os  pacientes  com  níveis  de  ensino
mais elevados  pareceram  ser  mais  aderentes  do  que  o  restante  do  grupo.
Conclusão:  Os  médicos  devem  estar  cientes  dos  fatores  relacionados  à  não  adesão,  a  ﬁm  de
alcanc¸ar melhores  resultados  do  tratamento.  Portanto,  com  base  em  nossos  resultados,  os
pacientes devem  ser  informados  de  que  os  medicamentos  devem  ser  usados  adequadamente
independentemente  do  benefício,  e  o  tratamento  deve  ser  programado  com  relac¸ão  às  ativi-
dades diárias,  especialmente  para  os  pacientes  que  cuidam  de  mais  de  dois  ﬁlhos.
© 2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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guidelines  and  who  had  not  previously  used  any  nasal  spraysntroduction
dherence  is  deﬁned  as  ‘the  extent  to  which  a per-
on’s  behavior--taking  medication,  following  a  diet,  and/or
xecuting  lifestyle  changes  --  corresponds  with  agreed
ecommendations  from  a  health  care  provider’.1 Non-
dherence  to  prescribed  medications  has  always  attracted
ess  attention  in  the  treatment  of  disease.  In  particular,  indi-
iduals  who  suffer  from  chronic  diseases  such  as  asthma,
ypertension,  diabetes  mellitus,  or  Chronic  Obstructive
ulmonary  Disease  (COPD)  have  certain  difﬁculties  with  con-
inuing  medical  treatment.  This  has  been  studied  in  several
apers,  and  in  one  study  regarding  asthma  patients,  it  was
eported  that  less  than  half  of  prescribed  medications  were
aken.2 Awareness  of  problems  with  adherence  is  as  impor-
ant  as  setting  up  the  right  treatment  modality  in  such
iseases.  It  is  obvious  that  non-adherence  will  have  a  nega-
ive  effect  on  long-term  treatment  results  and  obliviousness
bout  this  problem  will  lead  to  unnecessary  therapies  and
ncorrect  decisions.  Another  study  by  Evans  et  al.  indicated
 discontinuation  rate  of  39%  in  hypertension.3 The  rate  is
ven  higher  in  COPD  patients,  at  86%  according  to  Penning-
an  Beest  et  al.4 These  ﬁndings  emphasize  the  importance
f  adherence  to  medical  treatments.
The  most  commonly  used  scale  for  objectively
valuating  adherence  is  the  Morisky  Medication  Adher-
nce  Scale  (MMAS),  which  is  a  generic,  self-reported,
w
p
bedication-taking-behavior  scale  that  was  initially  vali-
ated  for  hypertension  but  is  used  for  a wide  variety  of
edical  conditions.5 The  original  version  consisted  of  four
tems,  and  it  was  eventually  updated  to  an  eight-item  scale
alled  the  MMAS-8  (Table  1).6 According  to  this  scale,  more
oints  indicate  lower  adherence  to  treatment.
Intranasal  corticosteroids  (ICS)  are  the  mainstay  med-
cation  for  allergic  rhinitis  (AR)  in  the  daily  routine  of
utpatient  otorhinolaryngology  clinics.  However,  adherence
o  this  treatment  has  not  been  well-studied.  In  the  present
tudy,  we  investigated  adherence  rates  and  factors  that  may
ead  to  non-adherence  in  an  adult  AR  population.
ethods
tudy  design  and  patient  population
his  prospective  study  was  conducted  on  adult  patients  who
ere  admitted  to  the  outpatient  clinic  of  the  otolaryngol-
gy  department  at  a  tertiary  hospital.  Patients  who  were
iagnosed  with  moderate  to  severe  persistent  AR  accord-
ng  to  the  ARIA  (allergic  rhinitis  and  its  impact  on  asthma)ere  enrolled.7 Informed  consent  was  obtained  from  all
atients  before  the  study  began.  The  institutional  review
oard  approved  this  study  (IRB  no.  665).
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Table  1  MMAS-8  scale.
Yes  No
1.  Do  you  sometimes  forget  to  take  your  pills?
2. People  sometimes  miss  taking  their  medications  for  reasons  other  than  forgetting.
Thinking over  the  past  two  weeks,  were  there  any  days  when  you  did  not  take  your
medicine?
3. Have  you  ever  cut  back  or  stopped  taking  medicine  without  telling  your  doctor
because you  felt  worse  when  you  took  it?
4. When  you  travel  or  leave  home,  do  you  sometimes  forget  to  bring  along  your
medicine?
5. Did  you  take  all  your  medicine  yesterday?
6. When  you  feel  like  your  symptoms  are  under  control  do  you  sometimes  stop  taking
your medicine?
7.  Taking  medicine  for  everyday  is  a  real  inconvenience  for  some  people.  Do  you  ever
fell hassled  about  sticking  to  your  treatment  plan?
8. How  often  do  you  fell  difﬁculty  remembering  to  take  all  your  medicine?
Never/rarely
Once  in  a  while
Sometimes
Usually
All  the  time
Table  2  Factors  related  to  adherence  level.
n  MMAS-8  score  p
Age ≤35  30  3.40  0.413
>35 29  3.89
Gender Female  25  3.28  0.387
Male  34  3.96
Maritial  status Single  19  3.50  0.827
Married  40  3.71
Multidrug  use Yes 26  3.75  0.987
No 33  3.42
Comorbidities Yes  20  3.68  0.778
No 39  3.55
Daily  working
hours
≤6  h  33  4.00  0.327
>6 h  26  3.41
Children ≤2  35  3.13  0.001a
>2  24  6.87
Side  effects Yes  12  5.07  0.150
No 47  3.23
Beneﬁt  from  the
drug
Yes  38  2.89  0.001a
No  21  6.90
Abroad  days  per ≤5  days  36  3.24  0.081
RAfter  a  detailed  clinical  history  and  examination  of  the
nasal  cavity,  sinuses,  nasopharynx,  and  chest  either  with  a
telescope  or  X-rays,  the  diagnosis  of  AR  was  conﬁrmed  with
evidence  of  speciﬁc  IgE  reactivity  to  allergens,  determined
on  a  Skin-Prick  Test  (SPT)  and/or  by  the  demonstration  of
serum-speciﬁc  IgE.  Patients  with  asthma,  nasal  septal  devi-
ation,  a  history  of  nasal  spray  use,  acute/chronic  sinusitis,  a
history  of  sinonasal  surgery,  or  a  history  of  sinonasal  malig-
nancy  were  excluded.  After  diagnosis,  the  patients  were
provided  with  mometasone  furoate  nasal  spray  at  a  dose  of
256  g  per  day,  administered  as  two  sprays  per  nostril  once
daily  in  the  morning  for  30  days.  All  patients  were  given  writ-
ten  standardized  instructions  on  how  to  use  the  medication.
At  the  end  of  the  therapy,  all  participants  were  seen  for  a
control  examination  and  were  asked  to  ﬁll  out  an  11  item
questionnaire  regarding  the  factors  that  may  have  inﬂu-
enced  their  adherence  to  the  treatment  (Table  2).  After  the
questionnaire,  each  patient  ﬁlled  out  the  Turkish-language-
validated  MMAS-8  form  and  the  scores  were  calculated
by  another  physician  who  was  blind  to  the  clinical  data.8
MMAS-8  is  a  practical  scale  comprised  of  8  yes/no  ques-
tions  regarding  patient’s  adherence  to  medical  treatment.
As  described  above  higher  scores  mean  less  adherence  to
treatment.  Each  factor  that  may  have  affected  adherence
to  the  prescribed  medication  was  evaluated  according  to  the
MMAS-8  score  and  all  variables  were  analyzed  statistically.
Statistical  analysis
Statistical  analysis  was  performed  using  the  Statistical  Pack-
age  for  the  Social  Sciences  version  15.0  (SPSS,  Inc.,  Chicago,
IL,  USA).  The  signiﬁcance  of  the  difference  between  groups
in  terms  of  median  values  was  determined  with  the
Kruskal--Wallis  test.  A  p-value  of  <0.05  was  considered  sig-
niﬁcant.
F
t
m
rmonth >5 days  23  4.92
a Statistically signiﬁcant.
esultsrom  82  patients  who  were  diagnosed  as  AR  in  our  outpa-
ient  clinic,  59  patients  (32  female  and  27  male)  with  a
ean  age  of  32.5  years  (range  21--52)  who  met  the  crite-
ia  and  come  back  for  assessment  at  30  days  were  included
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Table  3  MMAS-8  scores  according  to  education  level.
Educationa MMAS-8
Primary  school 3.11
Middle  school  6.71
High school  5.63
University/postgraduate  2.43b
a Education levels are shown according to the Turkish educa-
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Rtion system.
b Statistically signiﬁcant according to nonparametric tests.
n  the  study.  The  remainder  23  patients  were  excluded.
orty-two  patients  of  the  study  group  had  a  positive  SPT
nd  23  had  speciﬁc  IgE  reactivity  to  allergens  (6  patients
ad  both  positive  SPT  and  speciﬁc  IgE  reactivity).  The  mean
verall  MMAS-8  score  was  3.64.  The  factors  that  may  affect
dherence  and  the  related  MMAS-8  scores  are  summarized
n  Table  2.  When  the  scores  were  evaluated,  patients  liv-
ng  with  more  than  two  dependent  children,  who  did  not
eneﬁt  from  the  medication,  who  experienced  side  effects,
r  who  traveled  more  than  5  days  per  month  had  higher
cores  for  poor  adherence  (6.87,  6.90,  5.07,  and  4.92  points,
espectively).  When  all  questions  were  evaluated  from  the
tatistical  point  of  view,  two  factors  seemed  to  be  signiﬁcan-
ly  related  to  low  adherence:  number  of  dependent  children
p  = 0.001)  and  beneﬁt  from  the  medication  (p  =  0.001).  In
ur  study,  patients  with  more  than  two  dependent  chil-
ren  and  who  thought  that  the  medication  did  not  work
ere  more  likely  to  discontinue  their  therapy.  On  the  other
and,  patients  who  beneﬁted  from  the  medication,  those
ho  were  living  with  less  than  two  dependent  children,  and
hose  who  had  fewer  side  effects  were  more  adherent  to  the
herapy  according  to  MMAS-8  scores  (2.89,  3.13,  and  3.23
oints,  respectively).  Education  status  was  another  impor-
ant  factor.  Patients  with  higher  education  levels  seemed  to
e  more  adherent  than  the  rest  of  the  group  (Table  3).
iscussion
he  importance  of  adherence  to  medical  therapy  is  an  incon-
estable  element  that  may  affect  treatment  outcomes.  It
s  beyond  doubt  that  non-adherence  will  cause  prolonged
uration  of  treatment,  dissatisfaction  of  patients,  low
uality  of  life,  and  unnecessary  ﬁnancial  burdens  for  govern-
ents.  A  report  stated  that  more  than  half  of  patients  with
hronic  diseases  fail  to  continue  prescribed  medication.9
dherence  is  an  underestimated  factor  in  the  treatment
rotocols  for  various  diseases,  but  the  number  of  studies
nvestigating  this  phenomenon  has  gradually  increased  in
he  last  decade.  In  a  study  by  Christensen,  non-adherence  to
edical  treatment  regimens  was  reported  to  range  between
0%  and  40%  in  acute  illness  and  30%--60%  in  chronic  diseases.
oreover,  discontinuity  rates  were  as  high  as  80%  for  pre-
entive  treatments.10 There  are  numerous  determinants  of
dherence.  In  general,  these  can  be  divided  into  modiﬁable
nd  non-modiﬁable  factors,  such  as  the  type  of  prescribed
edication,  the  physician--patient  relationship,  the  cost  and
he  disease  itself  as  stated  by  Osterberg  et  al.11
Although  investigations  about  medical  adherence  have
ttracted  much  attention  lately,  adherence  to  ICS  in  AR  is PRESS
Ocak  E  et  al.
ess  well  studied.  A  few  reports  were  published  about  the
ole  of  patient  preference,  knowledge  level  and  willingness
o  adhere  to  the  therapy.12--14
Based  on  this  background,  we  investigated  the  variables
hat  may  be  related  to  medical  adherence  to  ICS  in  AR.  Our
ndings  suggested  that  the  number  of  children  dependent  on
he  patient  and  the  feeling  of  receiving  a  beneﬁt  from  the
rug  were  the  two  most  signiﬁcant  factors  relevant  to  adher-
nce.  Providing  beneﬁt  from  the  drug  is  a  subjective  term.
ur  data  demonstrates  that  it  is  an  important  factor  and  the
atients  who  were  in  the  feeling  that  the  medication  is  work-
ng,  seemed  to  be  more  adherent  to  the  treatment.  Thus,
e  suggest  scheduling  the  medication  plan  with  respect  to
aily  activities,  particularly  for  patients  caring  for  more  than
wo  children.  It  is  also  important  to  remind  the  patient  to
ake  the  prescribed  medications  properly,  regardless  of  the
eneﬁt.  In  order  to  avoid  non-adherence  due  to  the  above-
entioned  factors,  it  is  essential  to  reexamine  the  patient
t  regular  intervals  and  to  change  the  medicine  if  necessary.
It  is  important  to  note  that  neither  efﬁciency  nor  beneﬁt
rom  the  treatment  was  evaluated  in  this  study.  Therefore,
 homogenous  study  group  was  formed  in  terms  of  gender,
ge,  and  severity  of  disease.
Limitations  of  this  study  may  be  the  number  of  parti-
ipants,  the  possibility  of  interaction  between  the  factors,
nd  the  follow-up  period.  However,  as  mentioned  above,
eticulous  effort  was  made  to  prevent  heterogeneity  in  the
tudy  population.  On  the  other  hand,  a  precise  and  inde-
endent  evaluation  of  each  factor  requires  an  excessively
omogenous  study  group,  which  in  practice  would  reduce
he  number  of  patients.  Another  factor  is  the  lack  of  mul-
ivariate  statistical  analyses  due  to  the  limited  number  of
articipants.  Thus,  further  studies  with  larger  groups  and
onger  follow-up  periods  are  needed  to  perform  a  more  accu-
ate  evaluation  of  adherence  in  AR.
onclusion
he  treatment  of  a  disease  is  a  multifactorial  process  involv-
ng  the  appropriate  drugs,  timing,  the  patient’s  general
tatus,  and  the  healthcare  system.  After  the  diagnosis  is
ade  and  while  the  clinician  is  setting  up  the  treatment
egime,  it  must  be  kept  in  mind  that  non-adherence  will
rustrate  all  efforts.  Therefore,  we  suggest  keeping  in  mind
he  factors  related  to  non-adherence  when  providing  infor-
ation  about  prescribed  medications.
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